Immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial.
from Latest Science News -- ScienceDaily https://ift.tt/qIVl8sc
from Latest Science News -- ScienceDaily https://ift.tt/qIVl8sc
Comments
Post a Comment